Combined therapies in a murine model of blastoschizomycosis.
In a murine model of blastoschizomycosis, amphotericin B combined with micafungin, flucytosine or voriconazole did not improve the efficacy of fluconazole. However, such combinations can constitute therapeutic options for those cases where fluconazole fails.
Serena
Carolina
C
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain.
Rodríguez
M Mar
MM
Mariné
Marçal
M
Pastor
F Javier
FJ
Guarro
Josep
J
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005437:Flucytosine / Q000627:therapeutic use; D005847:Geotrichosis / Q000188:drug therapy*; D005848:Geotrichum / Q000187:drug effects*; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use; D008297:Male; D000077551:Micafungin; D051379:Mice; D008815:Mice, Inbred Strains; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use; D014250:Trichosporon / Q000187:drug effects*; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D005437:Flucytosine; D065819:Voriconazole; D000077551:Micafungin